Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Both GIP and GLP-2 reduce bone resorption (measured as CTX) in healthy adult individuals. In this study, we will investigate whether GIP and GLP-2 reduce CTX in children with spinal muscular atrophy, duchenne muscular dystrophy, or cerebral palsy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Maximum Age: 17
Healthy Volunteers: f
View:
• \- Diagnosis with Cerebral palsy (CP), Duchenne muscular dystrophy (DMD) or Spinal muscular atrophy (SMA) resulting in the need of a wheelchair
Locations
Other Locations
Denmark
Rigshospitalet
RECRUITING
Copenhagen
Contact Information
Primary
Bolette Hartmann
bhartmann@sund.ku.dk
+45 23264411
Backup
Charlotte Bayer Christiansen
cbchristiansen@sund.ku.dk
Time Frame
Start Date: 2023-03-24
Estimated Completion Date: 2026-12
Participants
Target number of participants: 8
Treatments
Experimental: Meal test
Oral liquid meal test
Experimental: Glucose dependent insulinotropic polypeptide (GIP) + Glucagon-like-peptide 2 (GLP-2)
Subcutaneous co-injection of GIP and GLP-2
Placebo_comparator: Placebo
Subcutaneous injection of saline
Related Therapeutic Areas
Sponsors
Leads: University of Copenhagen